Associated Press -- Merck & Co. is enjoying a spurt of new drug launches, partly due to its $41 billion November acquisition of New Jersey neighbor Schering-Plough Corp. Some have been on the market in the United States for a while, including blockbuster diabetes medicine Januvia, and are now being launched in other countries.
